Adis Journals
Updated EMS summary slide.pdf (702.67 kB)

Mitotane in adrenocortical carcinoma: a profile of its use

Download (702.67 kB)
online resource
posted on 2022-11-03, 20:52 authored by Matt Shirley



Funding The preparation of this review was not supported by any external funding.

Authorship and conflict of interest M. Shirley is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability Not applicable.


Additional information about this Adis Drug Review can be found here.



The adrenal cytotoxic agent mitotane (Lysodren®) has a central role in the systemic treatment of adrenocortical carcinoma (ACC), a rare and aggressive cancer of the adrenal glands. Although its precise mechanism of action remains unclear, mitotane has been evaluated and used for more than 60 years and, to date, is the only drug specifically approved for the treatment of ACC. Although ACC continues to be associated with a poor prognosis, mitotane has been shown to provide clinically significant benefit in a good proportion of ACC patients treated with the drug, both in the advanced (unresectable/metastatic) disease and adjuvant therapy settings. While mitotane has generally manageable tolerability with most adverse events (including neurotoxicity) being reversible with dose reduction or treatment interruption, regular monitoring of drug plasma concentrations during treatment is important to help ensure optimal use of mitotane while minimising the impact of drug toxicity.

 © Springer Nature Switzerland AG 2022 


Usage metrics

    Drugs & Therapy Perspectives




    Ref. manager